Thomas Liquard has been appointed chief executive officer of Alchemia, following the departure of Charles Walker. Mr. Liquard joined the company in December 2013 as chief operating officer, and brings significant commercial and managerial expertise having most recently served as senior director of Portfolio Development Lead Emerging Markets for the Established Products portfolio at Pfizer.
Mr. Liquard spent seven years at Pfizer holding various commercial roles of increasing responsibility. Mr. Liquard was a key member of the EP U.S. Brands P&L Leadership Team, where he planned the group's investment strategy culminating in the acquisition of NextWave Pharmaceuticals. Mr. Liquard also served in the New Product Planning and Portfolio Decision & Analysis organizations, where he was responsible for investment decisions on business development opportunities and internal development programs across multiple therapeutic areas including oncology, CNS and metabolic diseases.
"The company has been diligently preparing for its transformation into a broader commercial organization and with our pivotal Phase III trial data read-out on the horizon for HA-irinotecan, along with a developing oncology pipeline, we are delighted to make this appointment," said Santo J. Costa, Alchemia's incoming chairman. "Thomas' impressive background and strategic mindset makes him extremely qualified to lead Alchemia through this next stage of corporate growth. On behalf of the Board, I wish to thank Charlie for his service over the last year in helping guide our transition to products beyond fondaparinux."